ARX 788

Drug Profile

ARX 788

Alternative Names: Antibody-drug conjugate - Ambrx/Zhejiang Medicine; ARX788

Latest Information Update: 22 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ambrx
  • Developer Ambrx; Zhejiang Medicine
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Small molecules
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Gastric cancer

Most Recent Events

  • 23 Aug 2017 Ambrx plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) (NCT03255070)
  • 19 Aug 2016 The US FDA approves IND application for a phase I trial of ARX 788
  • 25 Mar 2016 IND application for ARX 788 in Breast cancer was approved in Australia and New Zealand before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top